Abaloparatide is a prescription medication, given as a daily injection, that builds new bone and is approved for osteoporosis at high fracture risk. It raises spine and hip bone density and reduced spine fractures in one large, manufacturer-funded trial program. Dizziness, rapid heartbeat and nausea are frequent but usually short-lived; treatment time is capped. No evidence shows benefit for people without osteoporosis. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Albumin-corrected serum calcium | 8.5–10.2 mg/dL | Safety check: hypercalcemia changes use |
| Intact parathyroid hormone | 15–65 pg/mL | Safety check: excludes hyperparathyroidism |
| 25-hydroxyvitamin D | ≥30 ng/mL | Safety check: corrects deficiency before treatment |
| Alkaline phosphatase | 44–147 IU/L | Safety check: unexplained elevation excludes use |
| Creatinine with eGFR | ≥60 mL/min/1.73 m² | Safety check: severe impairment changes use |
| 24-hour urine calcium | No established target; track change from own baseline | Safety check: hypercalciuria in stone formers |
| Serum uric acid | 2.4–6.0 mg/dL women, 3.4–7.0 mg/dL men | Expected to change: rises in women |
| P1NP | No established target; track rise from own baseline | Expected to change: confirms formation response |
| BMD by DXA (T-score) | T-score above −2.5 | Expected to change: primary efficacy measure |
| Seated blood pressure and pulse | Not specified in the ER | Shows susceptibility to orthostatic effects |
Cadence: Baseline before the first injection; seated blood pressure and pulse before and one hour after the first supervised dose; P1NP at 1–3 months; serum calcium at 1 month and whenever nausea, constipation or weakness suggests hypercalcemia; uric acid and kidney function at 6 months; DXA at 12 months and at the end of treatment, then every 1–2 years during follow-on antiresorptive therapy